Association between IL-6-174G/C polymorphism and risk of multiple sclerosis: A meta-Analysis

Genetic Testing and Molecular Biomarkers

Volumn 18, Issue 2, 2014, Pages 127-130

  Hu, Shan ^a   Chen, Ying ^b   Sun, Xu Dong ^a   Li, Fu Jin ^c   Shu, Qin Fen ^d   Liu, Xiao Li ^d   Jiang, Shou Feng ^e  

^a Hangzhou Air Force Aeromedicine Assessment and Training Centre   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c AnQiu Hospital of Traditional Chinese Medicine   (China)

^d ZHEJIANG HOSPITAL   (China)

^e Institute of Measurement Science of Zhejiang Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ARTICLE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HOMOZYGOTE; HUMAN; META ANALYSIS; MULTIPLE SCLEROSIS;

CASE-CONTROL STUDIES; ETHNIC GROUPS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-6; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84893749375     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2013.0387     Document Type: Article

References (25)

1. Bjartmar C, Wujek JR, Trapp BD (2003) Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 206:165-171.
2. Campbell IL, Stalder AK, Chiang CS, et al. (1997) Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. Mol Psychiatry 2:125-129.
3. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502-1517.
4. DerSimonian R, Laird N (1986) Meta-Analysis in clinical trials. Control Clin Trials 7:177-188.
5. Egger M, Davey Smith G, Schneider M, et al. (1997) Bias in metaanalysis detected by a simple, graphical test. BMJ 315:629-634.
6. Fishman D, Faulds G, Jeffery R, et al. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102: 1369-1376.
7. Giralt M, Ramos R, Quintana A, et al. (2013) Induction of atypical EAE mediated by transgenic production of IL-6 in astrocytes in the absence of systemic IL-6. Glia 61:587-600.
8. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-Analysis. Stat Med 21:1539-1558.
9. Izad M, Vodjgani M, Niknam MH, et al. (2010) Cytokines genes polymorphisms and risk of multiple sclerosis. Am J Med Sci 339:327-331.
10. Maimone D, Guazzi GC, Annunziata P (1997) IL-6 detection in multiple sclerosis brain. J Neurol Sci 146:59-65.
11. Makarycheva OY, Tsareva EY, Sudomoina MA, et al. (2010) Linkage and association of proinflammatory cytokines genes IL-6, IFNG and TNF with multiple sclerosis. Mol Biol 44: 728-733.
12. Malpass K (2013) Multiple sclerosis: T-cell resistance to regulation in RRMS linked to IL-6 pathway. Nat Rev Neurol 9:122.
13. Mantel N, Haenszel W(1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748.
14. Matsushita T, Tateishi T, Isobe N, et al. (2013) Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 8:e61835.
15. Mihailova S, Ivanova M, Mihaylova A, et al. (2005) Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. J Neuroimmunol 168: 138-143.
16. Mirowska-Guzel D, Gromadzka G, Mach A, et al. (2011) Association of IL1A, IL1B, ILRN, IL6, IL10 and TNF-Alpha polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. J Neuroimmunol 236:87-92.
17. Navikas V, Matusevicius D, Soderstrom M, et al. (1996) Increased interleukin-6mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis. J Neuroimmunol 64:63-69.
18. Okuda Y, Sakoda S, Saeki Y, et al. (2000) Enhancement of Th2 response in IL-6-deficient mice immunized with myelin oligodendrocyte glycoprotein. J Neuroimmunol 105:120-123.
19. Pender MP, Greer JM (2007) Immunology of multiple sclerosis. Curr Allergy Asthma Rep 7:285-292.
20. Schonrock LM, Gawlowski G, Bruck W (2000) Interleukin-6 expression in human multiple sclerosis lesions. Neurosci Lett 294:45-48.
21. Shahbazi M, Ebadi H, Fathi D, et al. (2010) HLA-DRB1 1501 intensifies the impact of IL-6 promoter polymorphism on the susceptibility to multiple sclerosis in an Iranian population. Mult Scler 16:1173-1177.
22. Stelmasiak Z, Koziol-Montewka M, Dobosz B, et al. (2000) Interleukin- 6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients. Med Sci Monit 6:1104-1108.
23. Stelmasiak Z, Koziol-Montewka M, Dobosz B, et al. (2001) IL-6 and sIL-6R concentration in the cerebrospinal fluid and serum of MS patients. Med Sci Monit 7:914-918.
24. Stepien A, Chalimoniuk M, Lubina-Dabrowska N, et al. (2013) Effects of interferon beta-1a and interferon beta-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing-remitting multiple sclerosis: a 3-year longitudinal study. Neuroimmunomodulation 20:213-222.
25. Yan J, Liu J, Lin CY, et al. (2012) Interleukin-6 gene promoter-572 C allele may play a role in rate of disease progression in multiple sclerosis. Int J Mol Sci 13:13667-13679.